
A new class of therapies to address cancer’s lethal ability to evolve resistance to treatment

ApoGen Biotechnologies, Inc. focused on the development of a new class of therapeutics targeting drivers of cancer genomic mutations. ApoGen built upon technologies developed at the University of Minnesota to develop drugs that block a key pathway that causes drug resistance.
“It’s not easy to get the funding to advance truly innovative science — especially to move from an a-ha moment to proof of concept. Granting agencies aren’t willing to take the risk, and biopharmaceutical companies need to see data supporting commercial potential. The Accelerator team believed that ApoGen’s science had significant potential. They were willing to provide funding and technical, operational, and intellectual support. Accelerator was the perfect fit for ApoGen.”
— Reuben Harris, Professor, University of Minnesota (co-founder)
“In my 20 years as an entrepreneur, Accelerator was the first firm that came to an initial meeting having studied our science. That helped me appreciate Accelerator’s philosophy of investing in cutting-edge science with real potential. That philosophy is critical to building a strategic partnership that can evolve based on the science and commercial opportunity.”
— John Santini, Co-Founder
SCIENTIFIC FOUNDERS


